# Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients

> **NCT01528800** · PHASE2 · COMPLETED · sponsor: **Dr. Rachel Holden** · enrollment: 85 (actual)

## Conditions studied

- End-stage Kidney Disease

## Interventions

- **DRUG:** Vitamin K1
- **DRUG:** Microcrystalline Methylcellulose

## Key facts

- **NCT ID:** NCT01528800
- **Lead sponsor:** Dr. Rachel Holden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2021-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01528800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01528800, "Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01528800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*